Proceedings of the 15 <sup>th</sup> European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals
The European Immunogenicity Platform (EIP) celebrated the 15th edition of its Open Symposium on Immunogenicity of Biopharmaceuticals and its associated one-day workshop on 22-24 February 2024 in Lisbon. The meeting attracted experts and newcomers across industry, regulatory agencies, and academia, who actively participated in 3 days of discussion on risk assessment, monitoring, and mitigation of unwanted immunogenicity of biologics. Besides oral presentations, poster sessions were held to maximize scientific exchange and networking opportunities. Therapeutic proteins and emerging gene and cell-based therapies present promising therapeutic options for addressing unmet medical needs or when conventional treatment approaches have failed. Nonetheless, the development of an immune response against these therapeutic agents is a significant concern, as it occurs in a considerable number of cases across various products and indications. The specific anti-drug antibodies that develop can lead to adverse safety events, inhibition of drug activity, or accelerated clearance, all of which result in a loss of treatment efficacy. The EIP serves as a forum for experts and newcomers in the immunogenicity field, fostering discussion among scientists from industry and academia, encouraging interactions with regulatory agencies, and disseminating knowledge and advancements in immunogenicity sciences to the broader scientific community. This report covers the main topics discussed during the EIP 15th Open Symposium on Immunogenicity of Biopharmaceuticals, and the one-day workshop on practical aspects of immunogenicity held prior to the conference. Key topics included immunogenicity testing, clinical relevance of immunogenicity, immunogenicity risk assessment and mitigation, and current regulatory considerations.
Authors
- Floris C. Loeff (ORCID: https://orcid.org/0000-0001-7059-2038)
- Marina Ichetovkin
- Elise Pepermans (ORCID: https://orcid.org/0000-0001-9572-296X)
- Arno Kromminga (ORCID: https://orcid.org/0000-0002-6058-869X)
- Daniel Yerly (ORCID: https://orcid.org/0000-0003-2857-0737)
- Michael Gutknecht (ORCID: https://orcid.org/0000-0002-7360-2235)
- Matthias Reichel
- Bernard Maillère (ORCID: https://orcid.org/0000-0001-5580-4194)
- Daniela Verthelyi (ORCID: https://orcid.org/0000-0002-5450-3071)
- Daniel Kramer (ORCID: https://orcid.org/0000-0002-1284-4871)
- Patrick Garidel (ORCID: https://orcid.org/0000-0001-9512-9533)
- Marc Pallardy (ORCID: https://orcid.org/0000-0001-8869-0365)
- Robert M. Nelson (ORCID: https://orcid.org/0000-0002-7856-555X)
- Manisha Saxena
- Vivek Nayak M (ORCID: https://orcid.org/0000-0003-4142-0143)
- Sophie Tourdot
- Francesca Minelli
- Noel Smith
- Axel Ducret (ORCID: https://orcid.org/0000-0003-1251-8520)
- Karien Bloem (ORCID: https://orcid.org/0000-0003-4325-8223)
- R. Wuttke
- Sofie Pattyn
- Joanna Grudzinska‐Goebel
- Lydia Michaut
- Timothy P. Hickling (ORCID: https://orcid.org/0000-0002-8918-2140)
- Michaël G. Tovey (ORCID: https://orcid.org/0000-0002-3058-0494)
- Alison Johnson (ORCID: https://orcid.org/0000-0002-1113-1191)
- Anne S. De Groot (ORCID: https://orcid.org/0000-0001-5911-1459)
- Lester Thoo (ORCID: https://orcid.org/0000-0001-9381-5943)
- Veerle Snoeck
- Zuben E. Sauna (ORCID: https://orcid.org/0000-0001-8202-5188)
- Anette Karle (ORCID: https://orcid.org/0000-0002-0567-9708)
- Issa Jyamubandi
- Morten Nielsen (ORCID: https://orcid.org/0000-0002-1250-4885)
- Amy S. Rosenberg
- Lysie Champion
- Frank Horling
- Ebru Aydin Kurtulmus
- Joao Pedras-Vasconelos
- Alain Poyau
Institutions
- Roche (Switzerland) (CH)
- Novartis (Switzerland) (CH)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- United States Food and Drug Administration (US)
- Center for Drug Evaluation and Research (US)
- Merck KGaA, Darmstadt (Germany) (DE)
- Pfizer (United States) (US)
- Université Paris Cité (FR)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Université Paris-Saclay (FR)
- Sanquin (NL)
- Novartis (China) (CN)
- Boehringer Ingelheim (Taiwan) (TW)
- Debiopharm (Switzerland) (CH)
- Svar Life Science (Netherlands) (NL)
- Blueprint Medicines (United States) (US)
- ADR-AC (Switzerland) (CH)
- Roche (United Kingdom) (GB)
- CEA Paris-Saclay (FR)
- EpiVax (United States) (US)
- Food and Drug Administration (TH)
- Boehringer Ingelheim (Australia) (AU)
- BioNTech (United States) (US)
- University of Turin (IT)
- Bayer (Germany) (DE)
- Lonza (Switzerland) (CH)
- Technical University of Denmark (DK)
Publication Details
- Journal
- mAbs
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1080/19420862.2025.2487604
- Citations
- 3
- Primary Topic
- vaccines and immunoinformatics approaches
- Type
- article
- Field-Weighted Citation Impact
- 2.42